scholarly journals Oral Mucositis Induced by Methotrexate: A Case Report

2018 ◽  
Vol 2 (8) ◽  
pp. 195-196
Author(s):  
Maya Verma
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Side Effects ◽  
Oral Mucositis ◽  
Dose Regimen ◽  
Low Dose ◽  
Therapeutic Benefit ◽  
Oral Ulceration ◽  
Neoplastic Diseases ◽  
Methotrexate Toxicity

The prescription of Methotrexate is well-recognized for various neoplastic diseases. For Rheumatoid arthritis, it is prescribed once a week, low-dose regimen for the treatment of psoriasis and rheumatoid arthritis. Apart from providing therapeutic benefit, it is not devoid of side effects like oral ulceration which may be due to over dosage regarding its once-weekly regime. This case report describes a patient with inherent Methotrexate toxicity that developed oral mucositis due to Methotrexate being given for rheumatoid arthritis.

scholarly journals Oral Ulceration Due to Methotrexate Treatment: A Report of 3 Cases and Literature Review

2015 ◽  
Vol 19 (2) ◽  
pp. 116-120 ◽  
Author(s):  
Theodoros Dervisoglou ◽  
Apostolos Matiakis
Keyword(s):  
Rheumatoid Arthritis ◽  
Literature Review ◽  
Dna Synthesis ◽  
Oral Mucositis ◽  
Adverse Reactions ◽  
Relevant Literature ◽  
Oral Ulceration ◽  
Neoplastic Diseases ◽  
Oral Ulcers ◽  
Methotrexate Treatment

SUMMARYMethotrexate (MTX) is an antimetabolite which interferes with DNA synthesis. It is used for the treatment of many diseases, such as psoriasis, rheumatoid arthritis and various neoplastic diseases. It may cause, among various adverse reactions, oral ulceration and oral mucositis. 3 cases of methotrexate related oral ulcers are reported along with a brief review of the relevant literature.

scholarly journals Low-dose IL-2 therapy limits the reduction in absolute numbers of circulating regulatory T cells in rheumatoid arthritis

2021 ◽  
Vol 13 ◽  
pp. 1759720X2110113
Author(s):  
Sheng-Xiao Zhang ◽  
Jia Wang ◽  
Cai-Hong Wang ◽  
Rui-Huan Jia ◽  
Ming Yan ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
T Cells ◽  
Side Effects ◽  
Regulatory T Cells ◽  
Disease Activity ◽  
Immune Tolerance ◽  
Low Dose ◽  
Fold Increase ◽  
Plain Language ◽  
T Subsets

Background: Circulating regulatory T cells (Tregs) are responsible for mediating immune tolerance and maintaining immunological homeostasis. Decreases in Tregs may be involved in the onset of rheumatoid arthritis (RA). Low-dose interleukin-2 (IL-2) has been considered for the treatment of inflammatory diseases mediated by T cells. This study focused on the status of circulating CD4+T subsets and the clinical feasibility of IL-2 therapies in patients with RA. Methods: The subjects included 888 patients with RA and 100 healthy controls (HCs); 233 RA patients received IL-2 treatment with 0.5 million international units (MIU)/day from days 1 through 5. The demographic features, disease activity, and levels of CD4+T cells measured by modified flow cytometry were collected in all RA patients before and after treatment. Results: RA patients had lower absolute Treg counts (but not Th17) compared with HCs, which was associated with disease activity; previously treated RA patients had the fewest circulating Tregs ( p < 0.05). Patients treated with low-dose IL-2 had a three-fold increase in absolute anti-inflammatory Treg counts, as well as a two-fold increase in the other CD4+T subsets. Moreover, post-treatment levels of markers of disease activity in RA patients treated with IL-2 were significantly lower than the baseline values ( p < 0.001), with no apparent side effects. Conclusion: Decreased absolute counts of circulating CD4+T lymphocyte subsets were observed in patients with RA. Circulating Tregs, which mediate immune tolerance, may be involved in the pathogenesis and progression of RA; however, this was ameliorated by low-dose IL-2, without obvious side effects. Plain language summary Low-dose IL-2 treatment for rheumatoid arthritis • Circulating Tregs may be involved in the pathogenesis and progression of RA. • The absolute count of Tregs was significantly correlated with disease activity measures. • Low-dose IL-2 was able to effectively expade Tregs and help for RA patients’ symptoms remission without evaluated side effects.

Methotrexate-induced oral mucositis in rheumatoid arthritis disease: Therapeutic strategy in a case report/Methotrexat-induzierte orale Mukositis bei rheumatoider Arthritis: Therapeutische Strategie in einem Fallbericht

2013 ◽  
Vol 2 (1) ◽  
Author(s):  
Margherita Gobbo ◽  
Giulia Ottaviani ◽  
Rossana Bussani ◽  
Gabriele Pozzato ◽  
Matteo Biasotto
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Oral Cavity ◽  
Oral Mucositis ◽  
Low Level Laser Therapy ◽  
Rheumatoid Arthritis Disease ◽  
Oral Pain ◽  
Relieve Pain ◽  
Level Laser

AbstractThe aim of this case report is to evaluate the efficacy of low-level laser therapy (LLLT) in the treatment of oral mucositis induced by methotrexate (MTX).A 52-year-old male patient, affected by rheumatoid arthritis and treated with corticosteroids and MTX, complained about severe oral pain and lesions for two months. He had been treated with topical and systemic corticosteroid therapy and chlorhexidine rinses with no significant improvement. He was not able to eat solid food or to wear his dental prosthesis. Examination of the oral cavity revealed retro-commissural and labial bilateral ulcerations and erythema and a 2-cm wide fibrous white lesion on the lower anterior vestibular ridge. Blood tests showed mild pancytopenia, and oral biopsies evidenced a “non-specific inflammatory condition” excluding any precancerous or paraneoplastic lesion or autoimmune diseases of the oral cavity. Previous medical records revealed that MTX had been discontinued many times due to mucositis since 2006, when the therapy had been started. This suggested a correlation between the onset of oral mucositis and MTX accumulation. LLLT was carried out for 4 consecutive days and three once-a-week follow-ups were performed.Lesions had completely healed during the second follow-up and the patient referred no pain at all from the 4th laser session on, therefore, the discontinuation of MTX had not been necessary.LLLT could represent an innovative technique to relieve pain related to MTX side effects thus avoiding dangerous discontinuation of therapy.

scholarly journals Rapid-onset supraventricular tachycardia following clozapine initiation and its management with verapamil: a case report

2019 ◽  
Vol 6 (2) ◽  
pp. 547
Author(s):  
Afnan A. Alwabili
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Adverse Effects ◽  
Supraventricular Tachycardia ◽  
Low Dose ◽  
Rapid Onset ◽  
Treatment Resistant ◽  
Early Stages ◽  
Drug Of Choice ◽  
Cardiovascular Side Effects

Clozapine is the drug of choice for treatment-resistant schizophrenia. However, the use of clozapine is limited by its serious adverse effects, which often underlie its discontinuation. The cardiovascular side effects that raise safety concerns include tachycardia, myocarditis and cardiomyopathy. The development of clozapine-induced tachycardia is usually observed on higher dosage especially at early stages of treatment. Here, author presented the case of a patient with treatment-resistant schizophrenia who developed asymptotic supraventricular tachycardia despite low dose of clozapine at the second day of treatment. Additionally, author explored the possibility of clozapine re-challenge in combination with verapamil treatment.

scholarly journals PANCITOPENIA SECONDARY TO THE USE OF LOW-DOSE METHOTREXATE IN A PATIENT WITH RHEUMATOID ARTHRITIS: CASE REPORT

2021 ◽  
Author(s):  
Rebecca de Souza Costa ◽  
Lucas Siqueira Geber Oliveira ◽  
Andre Machado Furtado ◽  
Gloria Maria de Oliveira
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Low Dose ◽  
Rheumatoid Arthritis Case ◽  
Dose Methotrexate

Oral mucositis in patients receiving low-dose methotrexate therapy for rheumatoid arthritis: report of 2 cases and literature review

2013 ◽  
Vol 115 (5) ◽  
pp. e28-e33 ◽  
Author(s):  
Matthias Troeltzsch ◽  
Gerhard von Blohn ◽  
Stefanie Kriegelstein ◽  
Timothy Woodlock ◽  
Volker Gassling ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Literature Review ◽  
Oral Mucositis ◽  
Low Dose ◽  
Methotrexate Therapy ◽  
Dose Methotrexate

scholarly journals Pneumocystis pneumonia induced by treatment with low-dose tacrolimus and methylprednisolone in a patient with rheumatoid arthritis: a case report

2013 ◽  
Vol 6 (1) ◽  
Author(s):  
Motoyasu Kato ◽  
Kazunori Tobino ◽  
Yuichi Fujimoto ◽  
Isao Kobayashi ◽  
Koji Sugano ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Low Dose ◽  
Pneumocystis Pneumonia

Can low-dose propranolol induce a manic syndrome? Case report of an unexpected side effect

2013 ◽  
Vol 25 (3) ◽  
pp. 184-186 ◽  
Author(s):  
Mahin Eslami Shahrbabaki ◽  
Fariborz Estilaee ◽  
Amir Eslami Shahrbabaki
Keyword(s):  
Single Dose ◽  
Case Report ◽  
Side Effects ◽  
Panic Disorder ◽  
Side Effect ◽  
Adrenergic Receptor ◽  
Low Dose ◽  
Manic Symptoms ◽  
Rare Side Effect ◽  
Adrenergic Antagonists

ObjectivesPropranolol, the first discovered b-adrenergic receptor antagonist, has been prescribed by physicians in various fields for more than three decades. It has been applied for treating psychiatric disorders including schizophrenia, mania and anxiety disorders, as well as for controlling withdrawal symptoms or other side effects.MethodsWe describe the case of an 11-year-old boy with bipolar-I disorder comorbid with panic disorder who developed manic symptoms with a single dose of 10 mg of propranolol.Results and ConclusionAlthough depression is a better-known side effect of b-adrenergic antagonists, clinicians should take mania as a rare side effect into consideration as well.

Sign in / Sign up

Export Citation Format

Share Document